Puig N, Agullo C, Contreras T, Perez JJ, Aires I, Calasanz MJ, Garcia-Sanz R, Castro S, Martinez-Lopez J, Rodriguez-Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, Gutierrez NC, Rios-Tamayo R, Rosinol L, Alvarez MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Inigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernandez MT, Lopez-Jimenez J, Reinoso M, Garcia-Mateo A, Ocio EM, Blade J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial. Haematologica. 2024 Dec 1;109(12):4056-4066. doi: 10.3324/haematol.2024.285742. PubMed PMID: 38988266; PubMed Central PMCID: PMC11609803.
AÑO: 2024; IF: 7.9
